Comments

Biomarin Pharmaceutical

Q: What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

BMRNNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$64.69

At close: Dec 18, 4:00 PM EDT

$64.69

0.000.00%

After Hours: 4:00 PM EDT

Biomarin Pharmaceutical (BMRN) Forecast

News Earnings Biomarin Pharmaceutical (BMRN) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Overview Rating

Speculative

Technicals Analysis

0100

Financials Analysis

0100

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock Quotes, Forecast and News Summary

Biomarin Pharmaceutical Stock (NASDAQ: BMRN) stock price, news, charts, stock research, profile.

Open	-
Close	-
Volume / Avg.	0 / 1.53M
Day Range	- - -
52 Wk Range	61.15 - 99.25
Market Cap	$12.33B
P/E Ratio	38.95
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	3.04%
Days to Cover	4.13

Recent News

Can BioMarin Stock Live Up to Wall Street's High Expectations?

BioMarin Pharmaceutical (NASDAQ:BMRN) has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock

MarketBeat

CAMP4 Analyst Highlights Rare Disease Platform Potential

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts project $1 billion in revenue for UCD drug by 2036.

Vandana Singh

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug

Sep

Oct

Nov

Dec

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.8

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	-
Close	-
Volume / Avg.	0 / 1.53M
Day Range	- - -
52 Wk Range	61.15 - 99.25
Market Cap	$12.33B
P/E Ratio	38.95
Dividend Yield	-
Exchange	NASDAQ
RSI	44
Short Interest	3.04%
Days to Cover	4.13

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

How do I buy Biomarin Pharmaceutical (BMRN) stock?

You can purchase shares of Biomarin Pharmaceutical (NASDAQ:BMRN) through any online brokerage.

View our list of the best stock brokerages

Who are Biomarin Pharmaceutical (BMRN) competitors?

Other companies in Biomarin Pharmaceutical’s space includes: Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Roivant Sciences (NASDAQ:ROIV) and Amgen (NASDAQ:AMGN).

What is the forecast, or price target, for Biomarin Pharmaceutical (BMRN) stock?

Biomarin Pharmaceutical has a consensus price target of $97.78.

What is the current price for Biomarin Pharmaceutical (BMRN)?

The stock price for Biomarin Pharmaceutical (NASDAQ: BMRN) is $64.69 last updated December 18, 2024 at 4:00 PM EST.

Does Biomarin Pharmaceutical (BMRN) pay a dividend?

There are no upcoming dividends for Biomarin Pharmaceutical.

When is Biomarin Pharmaceutical (NASDAQ:BMRN) reporting earnings?

Biomarin Pharmaceutical’s Q4 earnings are confirmed for Thursday, February 20, 2025.

Is Biomarin Pharmaceutical (BMRN) going to split?

There is no upcoming split for Biomarin Pharmaceutical.

What sector and industry does Biomarin Pharmaceutical (BMRN) operate in?

Biomarin Pharmaceutical is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.